Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.78 -0.09 (-0.15%)
Official Closing Price Updated: 7:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
66 67 Next >
Second Quarter Outlook For Biotech Stocks
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. 
Via Talk Markets
Is Aurinia Pharmaceuticals Up for Grabs? Shareholder Suggests a Quick Sale for a Bigger Payday
Via Benzinga
The Smartest Stocks to Buy With $20 Right Now and Hold Forever
These cheap stocks have the potential to skyrocket over the long haul. 
Via The Motley Fool
This Is What Whales Are Betting On Bristol-Myers Squibb
Via Benzinga
Thinking Of Buying Healthpeak Properties? Here Are The Properties And Tenants You'd Be Adding To Your Portfolio
Real estate investment trusts (REITs) are one of the most popular income-oriented types of stocks investors can purchase. Receiving monthly or quarterly dividend payments on a regular basis is... 
Via Benzinga
Where Bristol-Myers Squibb Stands With Analysts
Via Benzinga
This House of Representative Just Sold Up To $265K In Bristol-Myers Squibb Stock
Via Benzinga
2 Top Stocks to Buy in April and Hold Forever
The need for healthcare goods and/or services is here to stay. 
Via The Motley Fool
2 Ultra-Cheap Dividend Stocks to Buy in April
These two big pharma stocks are trading at steep discounts. 
Via The Motley Fool
Why Shares of Legend Biotech Jumped Wednesday
A leaked abstract on a phase 3 trial for the company's multiple myeloma drug Carvykti gave the stock a jolt. 
Via The Motley Fool
Legend Biotech Breaks Out After Leaked Documents Show Big CAR-T Benefit
The company could have the best-in-class CAR-T drug for multiple myeloma patients. 
Via Investor's Business Daily
Evaxion Biotech Says Personalized Cancer Immunotherapy Meets Primary Endpoint In Melanoma Patients
Via Benzinga
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb Unusual Options Activity For March 31
Via Benzinga
Bristol Myers' Flagship Opdivo Shows Long Term Durable Benefits In Lung Cancer Patients
Via Benzinga
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards. 
Via InvestorPlace
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials
This month, H.C. Wainwright & Co. 
Via Benzinga
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners. 
Via Talk Markets
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
From Bristol Myers Squibb
Via Business Wire
Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies
Via Benzinga
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial
From Bristol Myers Squibb
Via Business Wire
AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners
Via Benzinga
Could This Drug Candidate Be a Winner for These 2 Big Pharma Stocks?
These titans of big pharma just enrolled patients into phase 3 clinical trials for this promising blood thinner. 
Via The Motley Fool
Is Eli Lilly or Bristol Myers Squibb the Better Value Stock to Buy Right Now?
One of these big pharma stocks is considerably more attractive as a pure-play value investment. 
Via The Motley Fool
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
BioNTech Is Ripe For A Rebound In 2023
BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
By Julian Richard, Benzinga 
Via TheNewswire.com
Exposures Product Safety
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years? 
Via News Direct
Exposures Product Safety
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.